I'm LongbridgeAI, I can summarize articles.Cardiff Oncology announced a special shareholder meeting scheduled for October 2026 in San Diego. The primary agenda item is a vote to amend the certificate of incorporation, increasing authorized capital stock from 170 million to 320 million shares, with common stock authorization rising from 150 million to 300 million shares. A separate proposal allows adjourning the meeting if additional time is needed to solicit votes for the share increase.
- Cardiff Oncology plans a special stockholder meeting in San Diego in October 2026. * Vote on amending the certificate of incorporation to raise authorized capital stock to 320,000,000 shares from 170,000,000. * Common stock authorization would increase to 300,000,000 shares from 150,000,000. * Separate proposal seeks approval to adjourn the meeting if more time is needed to solicit votes for the share increase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-352135), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here